Reactive Arthritis

Comprehensive Medical Guide: Reactive Arthritis (ReA)

Reactive Arthritis (ReA), historically categorized under the umbrella of Reiter’s Syndrome, represents a sterile, inflammatory arthropathy triggered by an antecedent infection located elsewhere in the body. Unlike septic arthritis, where the pathogen is present within the synovial fluid, Reactive Arthritis is an immunologically mediated process. As an expert clinical specialist, it is imperative to view ReA not merely as a joint condition, but as a systemic manifestation of a post-infectious inflammatory cascade.

1. Clinical Definition and Etiology

Reactive Arthritis is defined as an acute, non-purulent arthritis complicating an infection, most commonly involving the urogenital or gastrointestinal tracts. It is classified as a seronegative spondyloarthropathy, sharing genetic associations with the Human Leukocyte Antigen (HLA)-B27 allele.

The Pathogenic Triggers

The condition is typically "triggered" by specific gram-negative, lipopolysaccharide-containing bacteria. The latency period between the primary infection and the onset of arthritic symptoms usually ranges from 1 to 4 weeks.

2. Pathophysiology: The Molecular Mimicry Hypothesis

The precise mechanism of ReA is complex and involves a triad of genetic predisposition, microbial insult, and aberrant immune response.

Molecular Mimicry

The leading theory suggests that the immune system, specifically T-lymphocytes, becomes primed to recognize bacterial antigens. Due to structural similarities between these bacterial proteins and self-antigens in the host (molecular mimicry), the immune system inadvertently attacks healthy synovial tissue, connective tissue, and ocular structures.

The Role of HLA-B27

Approximately 60–80% of patients with chronic or severe ReA are positive for the HLA-B27 antigen. While not diagnostic, this genetic marker significantly increases the risk of developing the condition following a triggering infection and is associated with a higher likelihood of axial involvement and disease chronicity.

Synovial Inflammation

Once the immune cascade is initiated, pro-inflammatory cytokines such as TNF-alpha, IL-1, and IL-6 are upregulated. This leads to synovial hypertrophy, infiltration of macrophages and T-cells, and the eventual clinical presentation of joint swelling, warmth, and pain.

3. Clinical Presentation and Staging

Classically, ReA is described by the triad: "Can't see, can't pee, can't climb a tree" (Conjunctivitis, Urethritis, and Arthritis). However, this classic triad is present in only about 30% of patients.

Standard Clinical Indications

1. Arthritis: Typically asymmetric and oligoarticular, predominantly affecting the lower extremities (knees, ankles, feet). Dactylitis ("sausage digit") is a hallmark sign.
2. Urogenital Manifestations: Sterile urethritis in men; cervicitis or salpingitis in women.
3. Ocular Involvement: Conjunctivitis (often mild and transient) or, more severely, anterior uveitis.
4. Mucocutaneous Lesions:
   • Circinate Balanitis: Shallow, painless ulcers on the glans penis.
   • Keratoderma Blennorrhagicum: Hyperkeratotic, waxy lesions on the soles and palms.
   • Oral Ulcers: Often painless and transient.

Clinical Staging

While there is no universally accepted "staging" system like cancer, clinicians categorize the disease by temporal progression:
* Acute Phase: Initial inflammatory response, usually resolving within 3–6 months.
* Chronic Phase: Persistence of symptoms beyond 6 months, often requiring disease-modifying anti-rheumatic drugs (DMARDs).

4. Diagnostic Assessment

There is no single "gold standard" test for Reactive Arthritis. It remains a clinical diagnosis supported by laboratory findings and physical examination.

Key Diagnostic Tests

• Synovial Fluid Analysis: Essential to rule out septic arthritis. In ReA, the fluid is inflammatory but sterile (no bacterial growth on culture).
• Microbiological Testing: Nucleic acid amplification tests (NAAT) for Chlamydia and stool cultures for gastrointestinal pathogens.
• HLA-B27 Typing: Used to assess prognosis and risk of chronic spondyloarthropathy.
• Inflammatory Markers: ESR (Erythrocyte Sedimentation Rate) and CRP (C-Reactive Protein) are typically elevated during the acute phase.

Differential Diagnosis

It is critical to differentiate ReA from other conditions that mimic its presentation:
* Septic Arthritis: Must be excluded via synovial fluid culture; septic arthritis is a medical emergency.
* Gonococcal Arthritis: Often presents with migratory polyarthritis and skin lesions; requires prompt antibiotic treatment.
* Psoriatic Arthritis: May present with dactylitis and oligoarthritis; lacks the antecedent infectious history.
* Ankylosing Spondylitis: Often presents with chronic back pain and stiffness.

5. Management and Therapeutic Strategy

The primary goal is the management of inflammation and the eradication of any remaining triggering infection.

Pharmacological Interventions

1. NSAIDs: First-line therapy for joint pain and inflammation (e.g., Naproxen, Indomethacin).
2. Antibiotics: Indicated for active urogenital infection. While they treat the primary infection, evidence suggests they have little effect on the established arthritis itself.
3. Corticosteroids: Intra-articular injections for localized joint pain or systemic steroids for severe systemic inflammation.
4. DMARDs: For patients with refractory or chronic disease, Sulfasalazine or Methotrexate may be initiated.
5. Biologics: TNF-alpha inhibitors are reserved for severe, treatment-resistant cases.

6. Risks, Side Effects, and Contraindications

• NSAID Risks: Long-term use carries significant gastrointestinal (ulceration), renal (nephrotoxicity), and cardiovascular risks.
• Immunosuppressant Risks: Patients on DMARDs or biologics are at an increased risk of opportunistic infections. Regular monitoring of complete blood counts (CBC) and liver function tests (LFTs) is mandatory.
• Contraindications: Systemic corticosteroids should be used with extreme caution in patients with uncontrolled hypertension or latent tuberculosis.

7. FAQ: Frequently Asked Questions

Q1: Is Reactive Arthritis contagious?
A1: The arthritis itself is not contagious. However, the initial infection that triggers it (e.g., Chlamydia) can be transmitted.

Q2: Will I have this forever?
A2: Most cases of ReA resolve within 6 months. A small percentage of patients (approx. 15–20%) may develop chronic, recurring symptoms.

Q3: Can I play sports with Reactive Arthritis?
A3: During the acute phase, rest is recommended. Once inflammation subsides, low-impact exercise is encouraged to maintain joint mobility.

Q4: Is there a specific diet that helps?
A4: There is no "Reactive Arthritis diet," but an anti-inflammatory diet rich in Omega-3 fatty acids may help manage systemic inflammation.

Q5: What is the significance of "sausage digits"?
A5: Dactylitis, or "sausage digit," is caused by inflammation of the entire finger or toe (enthesitis), which is a characteristic feature of spondyloarthropathies like ReA.

Q6: Does HLA-B27 mean I have Ankylosing Spondylitis?
A6: No. HLA-B27 is a genetic marker associated with several spondyloarthropathies, including ReA and AS. It increases your risk, but it is not a diagnosis.

Q7: Can I take antibiotics to prevent ReA?
A7: No. Antibiotics are only effective at treating the primary bacterial infection and do not prevent the autoimmune "reaction" that causes the arthritis.

Q8: Are women affected differently than men?
A8: Men are more frequently diagnosed with ReA following urogenital infections, while the incidence is more equal following gastrointestinal infections.

Q9: How is it distinguished from gout?
A9: Gout is caused by uric acid crystals, usually affecting the big toe. ReA is usually systemic, often follows an infection, and synovial fluid analysis would show crystals in gout but not in ReA.

Q10: Should I see a rheumatologist?
A10: Yes. If you suspect ReA, a rheumatologist is the specialist best equipped to manage the inflammatory process and prevent long-term joint damage.

8. Long-term Prognosis

The prognosis for Reactive Arthritis is generally favorable. The majority of patients achieve complete remission. However, patients with the HLA-B27 marker and those who experience severe initial symptoms are at a higher risk of developing a chronic, recurring spondyloarthropathy. Early diagnosis and prompt management of the inflammatory cascade are key to preventing structural joint damage and preserving long-term physical function.

Clinical Summary Table

Disclaimer: This guide is intended for educational purposes and reflects clinical standards. It does not replace professional medical diagnosis or treatment. Always consult with a board-certified rheumatologist for individual clinical cases.